Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06545916 · ClinicalTrials.gov registry record · Phase 2
Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder
A Phase 2 study of Alcohol Use Disorder, sponsored by Imbrium Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 7
- Study locations
NCT06545916: Active Phase 2 study of Alcohol Use Disorder, sponsored by Imbrium Therapeutics.
NCT06545916 is a Phase 2 study of Alcohol Use Disorder that is active but no longer recruiting, run by Imbrium Therapeutics. The registered enrollment target is 200 participants, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (39% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06545916, a Phase 2 study of Alcohol Use Disorder, is active but no longer recruiting, sponsored by Imbrium Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.
Conditions Studied
Interventions
- DRUG Sunobinop
- DRUG Placebo to match sunobinop
Study Locations (7)
Other
- Bio Terra Med SRL - Bucharest
- Spitalul Universitar De Urgenta Militar Central "Dr. Carol Davila" - Bucharest
- Cabinet Medical Individual Dr. Andreea Popa - Bucharest
Texas
- Inquest Clinical Research - Baytown
- Cebis Usa, Llc - Houston
New York
- Belmont Medical Office - Brooklyn
Ohio
- Ohio Clinical Trials - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What the registry record for NCT06545916 still lists
NCT06545916 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Sunobinop is the first listed.
NCT06545916 lists 7 locations in 4 states (Other, Texas, New York).
Frequently Asked Questions
What is clinical trial NCT06545916 about?
NCT06545916 is a clinical study titled "Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder". The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.
What is the current status of trial NCT06545916?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-10-14. Estimated completion is 2026-05.
What conditions does trial NCT06545916 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT06545916?
The interventions under investigation include: Sunobinop (DRUG), Placebo to match sunobinop (DRUG).
Who is sponsoring clinical trial NCT06545916?
This trial is sponsored by Imbrium Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06545916 being conducted?
This trial has 7 study locations across New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06545916's enrollment target sits among peer trials
200 43rd of 184 higher than 137 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI